Sophie Élise Michaud
Head of Medical Affairs, Galderma Canada
Continued innovation by companies like Galderma Canada is resulting in new treatments for Canadians living with inflammatory skin conditions.
Atopic dermatitis (AD) and prurigo nodularis (PN) are chronic inflammatory skin conditions that can involve a substantial, and sometimes not immediately visible, burden.
Both AD and PN are characterized by skin lesions and intense persistent itch, which can disrupt sleep, concentration, and overall well-being, and may affect daily functioning at school or in the workplace. People living with these conditions may experience sleep disturbances and social challenges and can experience impacts on their mental well-being.
Continued research and innovation are needed to advance treatment options for people living with chronic inflammatory skin diseases such as AD and PN. Ensuring equitable access to appropriate and effective care remains an important consideration.
Recent innovations are expanding the treatment options available for these conditions.
Supporting patient care
“Building on its experience in dermatology, Galderma supports ongoing research and the development of approaches to help improve the management of inflammatory skin conditions in Canada,” says Sophie Élise Michaud, Head of Medical Affairs at Galderma Canada. “These efforts reflect continued work toward addressing unmet patient needs and supporting the understanding of the burden associated with these conditions.”
Advances in this area rely on continued investment in research, along with a commitment to supporting patient care. Through its ongoing activities in dermatology, Galderma contributes to efforts aimed at improving the management of inflammatory skin conditions for Canadians.
Learn more about the impact of atopic dermatitis and inflammatory skin conditions, the importance of innovation in dermatology care, and the need to improve access to new treatment options for Canadians at galderma.com/canada.